NSE: SAILIFE · 13 November 2026
- Sai Life Sciences has risen 20.97% over 5 trading sessions; today's move is +1.24%.
- Sai Life Sciences released its unaudited financial results for the second quarter and half year ended September 30, 2026. Revenue from operations for Q2 FY27 reached ₹659 crore, marking a 23% increase year-on-year, while half-yearly revenue stood at ₹1,213 crore. Net profit for the quarter grew 17% year-on-year to ₹98 crore.
- Trading volume was 0.85 times the 20-day average daily volume.
Sai Life Sciences share price: 20.97% rise over 5 trading sessions
Sai Life Sciences Ltd. shares moved higher during Thursday's trading session, gaining 1.24% to close at ₹1,928.80 compared to its previous close of ₹1,905.20. The stock opened at ₹1,836.20 and fluctuated between an intraday low of ₹1,820.00 and a high of ₹1,954.80.
The broader market and sector benchmarks ended lower on November 13, 2026, with the Nifty declining by 0.61% and the Nifty Pharma sector index slipping by 0.49%. Despite the overall negative sentiment in the healthcare sector, Sai Life Sciences managed to buck the trend, building on its recent strong momentum that includes a 20.97% return over the past 5 trading days and a 34.68% return over the past 20 trading days.
The company's recent operational performance provides broader context for its market standing. For the second quarter ended September 30, 2026, Sai Life Sciences reported a 23% year-on-year growth in revenue from operations to ₹659 crore, while net profit rose 17% year-on-year to ₹98 crore. While these financial results from early November continue to frame investor discussions, today's specific price movement appears driven by ongoing market positioning and a technical rebound following recent gains.
15.05 lakh shares traded by 13 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 17.72 lakh shares (0.85 times). The five-day average daily volume was 56.82 lakh shares. Separately, the NSE report for 13 November 2026 showed 5.26 lakh shares delivered, representing 34.98% of that day’s traded volume. The same report recorded 78,599 trades.
The stock gained 1.24% in a down market session while outperforming the Nifty Pharma sector index, supported by healthy delivery participation and continued positive investor sentiment following its recent robust quarterly earnings.
Latest Company Developments
Sai Life Sciences released its unaudited financial results for the second quarter and half year ended September 30, 2026. Revenue from operations for Q2 FY27 reached ₹659 crore, marking a 23% increase year-on-year, while half-yearly revenue stood at ₹1,213 crore. Net profit for the quarter grew 17% year-on-year to ₹98 crore.
Demonstrates healthy top-line and bottom-line expansion across both CRO and CDMO segments.
The board approved the appointment of Mr. Sidhartha Das as Senior Vice President & Head of Human Resources, Mr. Vijay Kumar Suthari as Vice President & Head of Quality & Regulatory Affairs, and Mr. Sriram Gopalakrishnan as Senior Vice President of Corporate Communications, effective November 5, 2026.
Reinforces the senior leadership team across critical functional domains during its ongoing growth phase.
a press release dated November 05, 2026, titled "Press Release on Financial Results ".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 29.56% on 30 September 2026. This compares with 29.47% on 30 June 2026, a change of +0.09 percentage points.
The filing reported 31 MF/UTI holders.
Research & Brokerage Views
Maintained a positive view on Sai Life Sciences with a target price of ₹1620.
Named Sai Life Sciences as a top CRDMO pick, outlining multiple structural growth reasons.
What to Watch Next
- Execution of capacity expansion projects following ₹621 crore capex incurred in H1 FY27
- Progress on development and commercial pipeline scaling in the second half of the fiscal year
- Volume and delivery trends relative to the 20-day average volume of 1.77 million shares
- Sustained traction in global pharma customer engagements across CRO and CDMO segments
Other Dated Coverage
- Sai Life Sciences Share Price Today: Rises 20.48% in 3 Trading Sessions | 11 November 2026 — 11 November 2026
- Sai Life Sciences Share Price Today: Rises 15.21% in 2 Trading Sessions | 9 November 2026 — 9 November 2026
- Sai Life Sciences Share Price Today: Rises 15.46% in 2 Trading Sessions | 6 November 2026 — 6 November 2026
More Sai Life Sciences news and dated analysis →
Frequently Asked Questions
What is the latest Sai Life Sciences company news?
Sai Life Sciences released its unaudited financial results for the second quarter and half year ended September 30, 2026. Revenue from operations for Q2 FY27 reached ₹659 crore, marking a 23% increase year-on-year, while half-yearly revenue stood at ₹1,213 crore. Net profit for the quarter grew 17% year-on-year to ₹98 crore.
How strong was Sai Life Sciences’s trading volume?
15.05 lakh shares traded, 0.85 times the 20-day average daily volume. The price and volume data are dated 13 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.